Wednesday, 05 August 2020

Lupin launches Doxercalciferol Injection

19 December 2019 | News

It is the therapeutic generic equivalent of Sanofi Genzyme’s Hectorol® Injection

Lupin announced the launch of Doxercalciferol Injection, 4 mcg/2 mL (2 mcg/mL) Multi-dose Vials, having received an approval from the United States Food and Drug Administration (U.S. FDA) earlier.

Lupin’s Doxercalciferol Injection, 4 mcg/2 mL (2 mcg/mL) Multi-dose Vials, is the therapeutic generic equivalent of Sanofi Genzyme’s Hectorol® Injection, 4 mcg/2 mL (2 mcg/mL) Multi-dose Vials.

It is indicated for the treatment of secondary hyperparathyroidism in adult patients with CKD on dialysis. Doxercalciferol Injection, 4 mcg/2 mL (2 mcg/mL) Multi-dose Vials, (RLD: Hectorol®) had an annual sales of approximately USD 132 million in the U.S. (IQVIA MAT October 2019).

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account